Humanwell Healthcare (Group) Co. Ltd. has identified new kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, autoimmune diseases and inflammatory bowel disease.
Sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent as potentially useful for the treatment of pain.
Humanwell Healthcare (Group) Co. Ltd. has described new dual microtubule destabilizers (tubulin polymerization inhibitors) and proto-oncogene tyrosine-protein kinase Src inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, actinic keratosis, vitiligo and systemic lupus erythematosus, among others.
Research at Humanwell Healthcare (Group) Co. Ltd. has led to the identification of interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Research at Humanwell Healthcare (Group) Co. Ltd. has led to the development of heterocyclic 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of acute lung injury, diabetes, fibrosis, graft-vs.-host disease, heart failure, inflammatory bowel disease, alopecia and osteoporosis, among others.
Humanwell Healthcare (Group) Co. Ltd. researchers have prepared and tested AP2-associated protein kinase 1 (AAK1) inhibitors that are reported to be useful for the treatment of bipolar disorder, pain, schizophrenia, Alzheimer’s and Parkinson’s disease.
Humanwell Healthcare (Group) Co. Ltd. has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
Humanwell Healthcare (Group) Co. Ltd. has disclosed pyrimidopyrazine compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
